1. Current Status and Future Perspectives on Neoadjuvant Therapy in Lung Cancer 
Gideon M. Blumenthal, MD, Paul A. Bunn, MD, Jamie E. Chaft, MD, Caroline E. McCoach, MD, PhD, Edith A. Perez, MD, Giorgio V. Scagliotti, MD, PhD, David P. Carbone, MD, PhD, Hugo J.W.L. Aerts, PhD, Dara L. Aisner, MD, PhD, Jonas Bergh, MD, PhD, Donald A. Berry, PhD, Anthony Jarkowski, PharmD, BCOP, Nicholas Botwood, MD, Darren A.E. Cross, PhD, Max Diehn, MD, PhD, Nicole L. Drezner, MD, Robert C. Doebele, MD, PhD, Collin M. Blakely, MD, PhD, Wilfried E.E. Eberhardt, MD, Enriqueta Felip, MD, PhD, Luca Gianni, MD, Steven P. Keller, MD, PhD, Patrick J. Leavey, MD, Shakun Malik, MD, Francesco Pignatti, MD, MSc, Tatiana M. Prowell, MD, Mary W. Redman, PhD, Naiyer A. Rizvi, MD, Rafael Rosell, MD, Valerie Rusch, MD, Dirk de Ruysscher, MD, PhD, Lawrence H. Schwartz, MD, Rajeshwari Sridhara, PhD, Rolf A. Stahel, MD, Stephen Swisher, MD, Janis M. Taube, MD, MSc, William D. Travis, MD, Patricia Keegan, MD, Jacinta R. Wiens, PhD, Ignacio I. Wistuba, MD, Murry W. Wynes, PhD, Fred R. Hirsch, MD, PhD, Mark G. Kris, MD 
Journal of Thoracic Oncology 
Volume 13, Issue 12, Pages (December 2018)
DOI: /j.jtho
Copyright © Terms and Conditions

2. Figure 1
LCMC4 PROMISE. Schema of the proposed trial of the Lung Cancer Mutation Consortium (LCMC) to identify oncogenic drivers at diagnosis and to match targeted neoadjuvant therapies to the drivers detected in patients with early stage lung cancer. CT, computed tomography; PET, positron-emission tomography; ctDNA, circulating tumor DNA.
Journal of Thoracic Oncology  , DOI: ( /j.jtho )
Copyright © Terms and Conditions

3. Figure 2
Method for assessment of percentage of viable residual tumor in resection specimens following neoadjuvant therapy.59,60
Journal of Thoracic Oncology  , DOI: ( /j.jtho )
Copyright © Terms and Conditions